Cargando…

Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors

BACKGROUND: Receptor tyrosine kinases (RTKs) have a central role in cancer initiation and progression, since changes in their expression and activity potentially results in cell transformation. This concept is essential from a therapeutic standpoint, as clinical evidence indicates that tumours carry...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peron, Marica, Lovisa, Federica, Poli, Elena, Basso, Giuseppe, Bonvini, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493009/ https://www.ncbi.nlm.nih.gov/pubmed/26147305 http://dx.doi.org/10.1371/journal.pone.0132330

Ejemplares similares

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro
por: Peron, Marica, et al.
Publicado: (2012)

High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma
por: Bonvini, P, et al.
Publicado: (2013)

Autoantibody profiling of alveolar rhabdomyosarcoma patients unveils tumor-associated antigens with diagnostic and prognostic significance
por: Poli, Elena, et al.
Publicado: (2021)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Prognostic Value of Circulating IGFBP2 and Related Autoantibodies in Children with Metastatic Rhabdomyosarcomas
por: Poli, Elena, et al.
Publicado: (2020)

Immunoreactivity against fibroblast growth factor 8 in alveolar rhabdomyosarcoma patients and its involvement in tumor aggressiveness
por: Poli, Elena, et al.
Publicado: (2022)

Circulating miR-26a as Potential Prognostic Biomarkers in Pediatric Rhabdomyosarcoma
por: Tombolan, Lucia, et al.
Publicado: (2020)

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
por: Hou, Jinxuan, et al.
Publicado: (2011)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Recent advances in understanding and managing rhabdomyosarcoma
por: Hiniker, Susan M., et al.
Publicado: (2015)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma
por: Pomari, Elena, et al.
Publicado: (2017)

ALK Inhibitors, a Pharmaceutical Perspective
por: Ardini, Elena, et al.
Publicado: (2012)

Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma
por: Fanzani, Alessandro, et al.
Publicado: (2017)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma
por: Virgone, Calogero, et al.
Publicado: (2015)

Influencing the Fate of Cardiac and Neural Stem Cell Differentiation Using Small Molecule Inhibitors of ALK5
por: Zhong, Qixing, et al.
Publicado: (2018)

Recent advances in understanding and managing pediatric rhabdomyosarcoma
por: Gartrell, Jessica, et al.
Publicado: (2020)

Clinical significance of circulating tumor cells and cell‐free DNA in pediatric rhabdomyosarcoma
por: Tombolan, Lucia, et al.
Publicado: (2022)

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
por: Megiorni, Francesca, et al.
Publicado: (2015)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
por: Javanmardi, Niloufar, et al.
Publicado: (2019)

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Rhabdomyosarcoma Cells Produce Their Own Extracellular Matrix With Minimal Involvement of Cancer-Associated Fibroblasts: A Preliminary Study
por: D’Agostino, Stefania, et al.
Publicado: (2021)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
por: Liu, Tingting, et al.
Publicado: (2021)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng, Lei, et al.
Publicado: (2018)

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
por: Li, Samuel Q., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6u2r0po6srau1jd1j05g4dd2k2